BriaCell Therapeutics Corp - Ordinary Shares - New
BCTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$6.86M
Close$
$5.55
70.3% upside
Current Fair Value
70.3% upsideUndervalued by 70.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $6.86 Million |
|---|---|
| Enterprise Value | $-23,046,811.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-86.25 |
| Beta | 1.63 |
| Outstanding Shares | 2,802,337 |
Return
| Return on Equity | -98.10% |
|---|---|
| Return on Assets | -88.22% |
| Return on Invested Capital | -80.93% |
Valuation & Multiples
| P/E Ratio | -0.34 |
|---|---|
| PEG | -2.33 |
| Price to Sales | - |
| Price to Book Ratio | 0.33 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.94 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
March 11, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 13.80%▲ 13.45% |
|---|---|
| Total Invested | $1.62M▲ 2241.56% |
| Investors Holding | 14▲ 2.00% |
ESG Score
No data
About BriaCell Therapeutics Corp
BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.